Hillsdale Investment Management Inc. Purchases New Position in Vir Biotechnology, Inc. $VIR

Hillsdale Investment Management Inc. purchased a new position in Vir Biotechnology, Inc. (NASDAQ:VIR) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 161,096 shares of the company’s stock, valued at approximately $1,443,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. boosted its position in Vir Biotechnology by 25.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,761 shares of the company’s stock valued at $41,000 after acquiring an additional 1,390 shares in the last quarter. FNY Investment Advisers LLC purchased a new position in shares of Vir Biotechnology during the 3rd quarter worth approximately $38,000. Raymond James Financial Inc. bought a new position in shares of Vir Biotechnology in the 2nd quarter worth approximately $35,000. UMB Bank n.a. raised its position in shares of Vir Biotechnology by 1,418.7% in the 4th quarter. UMB Bank n.a. now owns 7,062 shares of the company’s stock worth $43,000 after acquiring an additional 6,597 shares in the last quarter. Finally, CWM LLC lifted its stake in shares of Vir Biotechnology by 23.0% in the 4th quarter. CWM LLC now owns 8,804 shares of the company’s stock valued at $53,000 after purchasing an additional 1,646 shares during the period. 65.32% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Vir Biotechnology

In related news, Director Janet Napolitano sold 3,200 shares of the company’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $9.45, for a total value of $30,240.00. Following the transaction, the director owned 21,216 shares in the company, valued at $200,491.20. The trade was a 13.11% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Vicki L. Sato sold 22,000 shares of the stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $10.05, for a total transaction of $221,100.00. Following the sale, the director directly owned 1,078,391 shares in the company, valued at $10,837,829.55. This trade represents a 2.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 25,579 shares of company stock valued at $254,922 over the last 90 days. Corporate insiders own 2.90% of the company’s stock.

Vir Biotechnology Stock Up 1.3%

Vir Biotechnology stock opened at $9.61 on Thursday. The company has a market capitalization of $1.62 billion, a P/E ratio of -3.07 and a beta of 1.62. The stock’s 50 day moving average is $9.33 and its 200 day moving average is $8.70. Vir Biotechnology, Inc. has a twelve month low of $4.16 and a twelve month high of $11.66.

Vir Biotechnology (NASDAQ:VIR) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.84). Vir Biotechnology had a negative net margin of 638.88% and a negative return on equity of 53.31%. The company had revenue of ($0.03) million for the quarter, compared to analysts’ expectations of $55.49 million. During the same quarter in the previous year, the firm posted ($0.88) EPS. As a group, equities analysts expect that Vir Biotechnology, Inc. will post -1.81 EPS for the current year.

Analyst Upgrades and Downgrades

VIR has been the topic of several research reports. Wall Street Zen lowered Vir Biotechnology from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Leerink Partners increased their price objective on Vir Biotechnology from $20.00 to $21.00 and gave the stock an “outperform” rating in a report on Wednesday, June 3rd. Morgan Stanley raised their price objective on Vir Biotechnology from $23.00 to $27.00 and gave the company an “overweight” rating in a research report on Thursday, June 11th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Vir Biotechnology in a report on Wednesday, July 8th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Vir Biotechnology presently has a consensus rating of “Moderate Buy” and an average target price of $20.88.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.